ProMIS Neurosciences presented preclinical data at the 2024 Alzheimer’s Association International Conference, AAIC, that further supports the potential therapeutic advantage of the Company’s novel approach to optimization of an Alzheimer’s disease vaccine for maximum targeting of toxic amyloid-beta oligomers, ABO. The results from the study showed that vaccination with ABO-restricted conformational B cell epitopes produced strong antibody responses with no measurable pro-inflammatory T cell responses against AB. Importantly, immunization with epitope 301, the target of PMN310, alone was sufficient to produce maximal reactivity against brain ABO.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PMN:
- ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference
- ProMIS Neurosciences Advances in Alzheimer’s Treatment Trial
- ProMIS Neurosciences announces up to $122.7M private placement financing
- ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer’s Trial
- ProMIS Neurosciences reports data from its Phase 1a Alzheimer’s trial
Questions or Comments about the article? Write to editor@tipranks.com